IRAK-1 Antibody (YA7436)
(Synonyms: IRAK, IRAK1, Interleukin-1 receptor-associated kinase 1, IRAK-1)IRAK-1 Antibody (YA7436) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to IRAK-1.
-
Host:
Rabbit
-
Isotype:
IgG
-
Application:
WB, ICC/IF, IP, ELISA
-
Reactivity :
Human
-
Formulation:
Supplied in PBS (pH7.4) containing 50% glycerol, 0.05% Proclin 300, 0.05%BSA
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
WB
WB: Western Blot
|
ICC/IF
ICC/IF: Immunocytochemistry/
Immunofluorescence |
ELISA
ELISA: Enzyme Linked Immunosorbent Assay
|
IP
IP: Immunoprecipitation
|
|---|---|---|---|---|
| Dilution Ratio | 1:2000-1:10000 | 1:200-1:1000 | 1:5000-1:20000 | 1:50-1:200 |
Product Details
IRAK-1 Antibody (YA7436) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to IRAK-1.
-
Host Rabbit
-
Clonality Monoclonal,Recombinant
-
Species ReactivityHuman
-
Observed Molecular WeightObserved band size: 77 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 77 kDa
The exact sequence is proprietary to MCE.
Endogenous
Protein A affinity purified
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS (pH7.4) containing 50% glycerol, 0.05% Proclin 300, 0.05%BSA
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
Interleukin-1 receptor-associated kinase 1 (IRAK1) is a serine-threonine kinase that mediates signaling downstream of Toll-like receptors (TLRs) and interleukin-1 receptor (IL-1R) complexes, promoting innate immune and inflammatory responses[1][2]. Mechanistically, IRAK1 interacts with the adaptor protein MyD88 and is recruited to the myddosome, where it undergoes phosphorylation and contributes to the activation of NF-κB and MAPK pathways[2][3]. Compared with its paralog IRAK4, IRAK1 exhibits distinct roles in hematologic malignancies, being preferentially expressed and required for maintaining viability and progenitor function in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) [4][5]. IRAK1 also regulates cancer stemness and chemoresistance in hepatocellular carcinoma through the IRAK1/IRAK4/AP-1/AKR1B10 signaling cascade, influencing self-renewal and tumorigenicity[6]. Alternative splicing generates the IRAK1b isoform, which is kinase-inactive but stable, adding regulatory complexity to IL-1 signaling[7]. Pharmacologically, selective IRAK1 inhibitors, including dual IRAK1/4 compounds and covalent degraders, effectively suppress inflammatory responses, enhance chemotherapy sensitivity, and reduce leukemic or tumor-initiating cell function in preclinical models[8][9][10][5][11][12]. These findings underscore the importance of IRAK1 in innate immunity, oncogenesis, and as a target for therapeutic intervention, while differentiating its function and regulation from other IRAK family members[13][4][5].
-
Subcellular Localization
Cytoplasm,Nucleus,Lipid droplet
-
Expression
Tissue_Specificity: Isoform 1 and isoform 2 are ubiquitously expressed in all tissues examined, with isoform 1 being more strongly expressed than isoform 2 -
Isoforms & Post-Translational Modification
P51617 has four isomers: P51617-1: 76537 Da (predicted); P51617-2: 73421 Da (predicted); P51617-3: 74560 Da (predicted); P51617-4: 68022 Da (predicted).
Following recruitment on the activated receptor complex, phosphorylated on Thr-209, probably by IRAK4, resulting in a conformational change of the kinase domain, allowing further phosphorylations to take place丨Polyubiquitinated by TRAF6 after cell stimulation with IL-1-beta by PELI1, PELI2 and PELI3 -
Subunit
Homodimer (By similarity)
-
SwissProt ID
-
Synonyms
IRAK, IRAK1, Interleukin-1 receptor-associated kinase 1, IRAK-1
Documentation
References
[1]. Singer JW, et al. Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy. Oncotarget. 2018 Sep 7;9(70):33416-33439. [Content Brief]
[2]. Ordureau A, et al. The IRAK-catalysed activation of the E3 ligase function of Pellino isoforms induces the Lys63-linked polyubiquitination of IRAK1. Biochem J. 2008 Jan 1;409(1):43-52. [Content Brief]
[3]. Hou Y, et al. IRAK Inhibitor Protects the Intestinal Tract of Necrotizing Enterocolitis by Inhibiting the Toll-Like Receptor (TLR) Inflammatory Signaling Pathway in Rats. Med Sci Monit. 2018 May 22;24:3366-3373. [Content Brief]
[4]. Hermans A, et al. A 3D-Printed and Freely Available Device to Measure the Zebrafish Optokinetic Response Before and After Injury. Zebrafish. 2024 Apr;21(2):144-148. [Content Brief]
[5]. Gosu V, et al. Molecular evolution and structural features of IRAK family members. PLoS One. 2012;7(11):e49771. [Content Brief]
[6]. Rhyasen GW, et al. Differential IRAK signaling in hematologic malignancies. Exp Hematol. 2013 Dec;41(12):1005-7. [Content Brief]
[7]. Cheng BY, et al. IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma. Cancer Res. 2018 May 1;78(9):2332-2342. [Content Brief]
[8]. Jensen LE, et al. IRAK1b, a novel alternative splice variant of interleukin-1 receptor-associated kinase (IRAK), mediates interleukin-1 signaling and has prolonged stability. J Biol Chem. 2001 Aug 3;276(31):29037-44. [Content Brief]
[9]. Kim KM, et al. Recent Advances in IRAK1: Pharmacological and Therapeutic Aspects. Molecules. 2024 May 9;29(10):2226. [Content Brief]
[10]. Sutter PJ, et al. Optimization of IRAK1/4/pan-FLT3 kinase inhibitors as treatments for acute myeloid leukemia. Bioorg Med Chem Lett. 2025 Dec 15;129:130355. [Content Brief]
[11]. Bennett J, et al. Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML. Blood. 2023 Sep 14;142(11):989-1007. [Content Brief]
[12]. Yan B, et al. Inhibition of IRAK 1/4 alleviates colitis by inhibiting TLR4/ NF-κB pathway and protecting the intestinal barrier. Bosn J Basic Med Sci. 2022 Oct 23;22(6):872-881. [Content Brief]
Powered by Bioz
